Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 17 citing articles:

Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer’s disease: a systematic review and network meta-analysis of randomized controlled trials
Wenting Cai, Hui Zhang, Yan Wu, et al.
Frontiers in Aging Neuroscience (2025) Vol. 16
Open Access | Times Cited: 1
Impact of Peripheral Inflammation on Blood–Brain Barrier Dysfunction and Its Role in Neurodegenerative Diseases
Ana Isabel Beltrán-Velasco, Vicente Javier Clemente‐Suárez
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2440-2440
Open Access | Times Cited: 1
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Amin Mahmood Thawabteh, Aseel Wasel Ghanem, Sara AbuMadi, et al.
Molecules (2024) Vol. 29, Iss. 21, pp. 5131-5131
Open Access | Times Cited: 7
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Sarfaraz K. Niazi, Zamara Mariam, Matthias Magoola
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6683-6683
Open Access | Times Cited: 6
The controversy around anti-amyloid antibodies for treating Alzheimer’s disease
Philip Hunter
EMBO Reports (2024)
Closed Access | Times Cited: 4
The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis
Chih‐Wei Hsu, Tien‐Wei Hsu, Yu‐Chen Kao, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100195-100195
Open Access
Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective
Amy Bobbins, Miranda Davies, Elizabeth Lynn, et al.
British Journal of Clinical Pharmacology (2025)
Open Access
A calmodulin-derived peptide TI-16 inhibits alzheimer's disease progression by decreasing aβ burden and restoring calcium dyshomeostasis
Jingyang Su, Jun Wei, Bowen Zhang, et al.
Bioorganic Chemistry (2025), pp. 108502-108502
Closed Access
Alzheimer’s Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2–7 Binding Affinity
Victor L. B. França, Eveline M. Bezerra, Roner F. da Costa, et al.
ACS Chemical Neuroscience (2024)
Open Access | Times Cited: 3
Nanocarrier-mediated siRNA delivery: a new approach for the treatment of traumatic brain injury–related Alzheimer's disease
Jie Jin, Huajing Zhang, Qianying Lu, et al.
Neural Regeneration Research (2024) Vol. 20, Iss. 9, pp. 2538-2555
Open Access | Times Cited: 3
Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials
Wenting Cai, Hui Zhang, Yan Wu, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Identification of a linear B-cell epitope on the “puff” loop of the Senecavirus A VP2 protein involved in receptor binding
Han-Rong Zhou, Mingxia Sun, Shibo Su, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 1
Lecanemab in Alzheimer’s disease: a profile of its use
Hannah A. Blair
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 10, pp. 393-400
Closed Access | Times Cited: 1
Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs—Protocols and Advice for the FDA to Meet the ALS Act Vision
Sarfaraz K. Niazi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10211-10211
Open Access | Times Cited: 1
News in geriatric medicine - what's new in dementia?
Katarína Bielaková, Ondřej Ludka
Vnitřní lékařství (2024) Vol. 70, Iss. 4, pp. 260-263
Open Access
Clinical Benefits and Risks of Anti-Amyloid Antibodies in Sporadic Alzheimer’s Disease: Systematic Review and Network Meta-Analysis with Web Application (Preprint)
Danko Jeremic, Juan D. Navarro‐López, Lydia Jiménez‐Díaz
Journal of Medical Internet Research (2024)
Open Access
The complexity of Alzheiemer's disease: New frontiers
Elka Stefanova
Medicinski podmladak (2024) Vol. 75, Iss. 5, pp. 76-83
Open Access
Page 1

Scroll to top